Genentech DRC A PHASE III, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINOPATHY (PAVILION)
Research Grant
Awarded By
Genentech, Inc.
Start Date
January 1, 2020
End Date
May 31, 2026
Awarded By
Genentech, Inc.
Start Date
January 1, 2020
End Date
May 31, 2026